Zdrowie i gospodarka · 01/07/2016

FDA Releases Draft Guidance for Industry on Recurrent Herpes Labialis Treatment and Prevention

The Food and Drug Administration (FDA) has released a draft guidance document to help pharmaceutical companies develop treatments and preventions for recurrent herpes labialis, a common skin condition. The guidance outlines necessary studies and trials for antiviral drug products to receive FDA approval.